Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
MerusN. V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands.
Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma.
In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers.
The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 1, 24 | -0.81 Decreased by -22.73% | -0.76 Decreased by -6.58% |
| May 8, 24 | -0.59 Increased by +31.40% | -0.81 Increased by +27.16% |
| Feb 28, 24 | -1.04 Increased by +42.54% | -0.74 Decreased by -40.54% |
| Nov 2, 23 | -0.43 Increased by +18.87% | -0.73 Increased by +41.10% |
| Aug 7, 23 | -0.66 Decreased by -407.69% | -0.88 Increased by +25.00% |
| May 4, 23 | -0.86 Decreased by -100.00% | -1.02 Increased by +15.69% |
| Feb 28, 23 | -1.81 Decreased by -432.35% | -0.83 Decreased by -118.07% |
| Nov 3, 22 | -0.53 Decreased by -35.90% | -0.63 Increased by +15.87% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 11.77 M Increased by +6.70% | -99.91 M Decreased by -334.14% | Decreased by -848.67% Decreased by -306.89% |
| Jun 30, 24 | 7.33 M Decreased by -30.01% | -50.04 M Decreased by -56.22% | Decreased by -682.52% Decreased by -123.21% |
| Mar 31, 24 | 7.89 M Decreased by -41.56% | -34.46 M Increased by +13.30% | Decreased by -436.76% Decreased by -48.36% |
| Dec 31, 23 | 8.94 M Decreased by -16.19% | -60.15 M Increased by +26.62% | Decreased by -672.93% Increased by +12.44% |
| Sep 30, 23 | 11.03 M Increased by +67.65% | -23.01 M Increased by +6.51% | Decreased by -208.57% Increased by +44.24% |
| Jun 30, 23 | 10.48 M Decreased by -17.41% | -32.03 M Decreased by -460.61% | Decreased by -305.78% Decreased by -578.76% |
| Mar 31, 23 | 13.50 M Increased by +15.82% | -39.74 M Decreased by -110.35% | Decreased by -294.40% Decreased by -81.61% |
| Dec 31, 22 | 10.67 M Decreased by -27.49% | -81.97 M Decreased by -468.42% | Decreased by -768.54% Decreased by -683.88% |